Published in Cancer Weekly, February 8th, 2005
The collaboration between Exelixis and GlaxoSmithKline (GSK) was established in October 2002 to discover and develop novel therapeutics in the areas of vascular biology, inflammatory disease, and oncology.
Under the terms of the original agreement, a 4-month option period began in October, 2004 for GSK to elect whether or not to expand the collaboration. The amended collaboration does not strictly adhere to either one of the options originally envisioned. The amended collaboration provides accelerated milestone payments to Exelixis and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.